Structures by: Smith M. M.
Total: 43
(4-bromo-PhC(CN)(=NOH)), 3-bromo-5-methoxypyridine
(C8H5BrN2O)(C6H6BrNO)
CrystEngComm (2009) 11, 3 439-443
a=6.9907(6)Å b=8.0552(7)Å c=15.3027(13)Å
α=79.305(5)° β=89.038(5)° γ=64.660(5)°
(4-bromo-PhC(CN)(=NOH)), 1-(4-bromobenzyl)-2- methylbenzimidazole
(C8H5BrN2O)(C15H13BrN2)
CrystEngComm (2009) 11, 3 439-443
a=4.9374(6)Å b=22.597(3)Å c=19.233(2)Å
α=90.00° β=96.869(2)° γ=90.00°
4-bromo-PhC(CN)(N=OH), (3-((5,6-dimethylbenzimidazol-1- yl)methyl)PhCN
(C8H5N2OBr)(C17H15N3)
CrystEngComm (2009) 11, 3 439-443
a=6.039(3)Å b=13.982(6)Å c=14.166(6)Å
α=70.067(19)° β=83.78(3)° γ=82.22(3)°
(4-bromo-PhC(CN)(=NOH)), 1-(4-bromobenzyl)benzimidazole
(C8H5BrN2O)(C14H11BrN2)
CrystEngComm (2009) 11, 3 439-443
a=5.3033(6)Å b=13.2294(15)Å c=15.0601(17)Å
α=102.536(2)° β=99.505(2)° γ=94.752(2)°
(2-fluoro-PhC(CN)(=NOH))2, 1,2-di(4-pyridyl)ethene
(C8H5N2OF)2(C12H10N2)
CrystEngComm (2009) 11, 3 439-443
a=3.8189(6)Å b=11.2941(18)Å c=14.107(2)Å
α=98.884(10)° β=93.147(11)° γ=94.624(10)°
481 1,4-di((1-benzimidazolyl)methyl)benzene, (3-chloro- PhC(CN)(=NOH))2
(C22H18N4)(C8H5N2OCl)2
CrystEngComm (2009) 11, 3 439-443
a=13.6335(10)Å b=4.4402(3)Å c=27.297(2)Å
α=90.00° β=94.084(3)° γ=90.00°
MS 512 1-(4-pyridylmethyl)-5,6-Me2benzimidazole, 4-F- PhC(CN)(NOH)
(C15H15N3)(C8H5N2OF)
CrystEngComm (2009) 11, 3 439-443
a=16.1659(12)Å b=6.4146(5)Å c=21.0074(16)Å
α=90.00° β=105.945(5)° γ=90.00°
MS 9-37 1,3,5-tri(C(CN)=NOH)benzene, 1,4-di(4-pyridyl)ethane
(C12H6N6O3)2(C12H12N2)3(C2H3N)2.25
CrystEngComm (2012) 14, 1 71
a=11.310(2)Å b=17.162(3)Å c=17.335(3)Å
α=88.010(10)° β=82.742(10)° γ=70.891(10)°
Bis(3-((2-methylbenzimidazol-1-yl)methyl)benzamide) silver(i) BF4
(C16H15N3O)2(AgBF4)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=11.666(2)Å b=12.237(2)Å c=13.013(2)Å
α=109.136(13)° β=114.266(8)° γ=92.310(14)°
Bis(4-((6,7-dimethylbenzimidazol-1-yl)methyl)benzamide), AgBF4
(C17H17N3O)2Ag(BF4)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=9.9140(7)Å b=8.4229(6)Å c=19.7055(13)Å
α=90.00° β=102.108(3)° γ=90.00°
(4-((5,6-dimethylbenzimidazol-1-yl)methyl)benzamide)2, AgAsF6
(C17H17N3O)2AgAsF6
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=9.1269(6)Å b=9.2459(5)Å c=10.0615(7)Å
α=97.921(4)° β=89.950(4)° γ=98.904(4)°
Bis(2-methyl-3-((benzamide-4-yl)methyl)benzimidaol-1- yl)silver(i) (AsF6)
(C16H15N3O)2Ag(AsF6)(CH4O)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=7.3084(4)Å b=18.5828(11)Å c=25.1620(15)Å
α=90.00° β=96.8060(10)° γ=90.00°
Bis(2-methyl-3-((benzamide-4-yl)methyl)benzimidaol-1- yl)silver(i) (SbF6)
(C16H15N3O)2Ag(SbF6)(O)3
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=7.5069(5)Å b=18.6924(12)Å c=24.9808(17)Å
α=90.00° β=98.4920(10)° γ=90.00°
Bis(2-methyl-3-((benzamide-3-yl)methyl)benzimidaol-1- yl)silver(i) (SbF6)
(C16H15N3O)2Ag(SbF6)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=9.2644(4)Å b=13.2045(6)Å c=14.2022(6)Å
α=74.5580(10)° β=81.7510(10)° γ=72.2750(10)°
Bis(4-((2-methylbenzimidazol-1-yl)methyl)benzamide) silver(i) BF4, H2O
(C16H15N3O)2(AgBF4)(O)3.4
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=40.141(3)Å b=4.9633(5)Å c=18.6857(19)Å
α=90.00° β=96.855(6)° γ=90.00°
3-((2-methylbenzimidazol-1-yl)methyl)benzamide, Ag (AsF6)
(C16H15N3O)2Ag(AsF6)(CH4O)0.5
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=11.8443(8)Å b=12.1157(7)Å c=13.3329(8)Å
α=66.333(3)° β=69.670(3)° γ=87.960(3)°
621 4-carboxy-PhC(CN)=NOH, 1-((4-pyridyl)methyl)-5,6-Me2- benzimidazole
(C9H6N2O3)(C15H15N3)
Chemical communications (Cambridge, England) (2007) 38 3936-3938
a=11.0553(13)Å b=7.3121(9)Å c=13.2662(17)Å
α=90.00° β=94.693(7)° γ=90.00°
1-((4-pyridyl)methyl)-2-phenylimidazole, 4-hydroxybenzoic acid
(C15H13N3)(C7H6O3)
Chemical communications (Cambridge, England) (2007) 38 3936-3938
a=8.0137(8)Å b=9.8024(9)Å c=12.0784(13)Å
α=82.364(6)° β=86.045(7)° γ=75.888(6)°
442 1-((4-pyridyl)methyl)-5,6-dimethylbenzimidazole, 4- bromoPhC(CN)(=NOH)
C23H20BrN5O
Chemical communications (Cambridge, England) (2007) 38 3936-3938
a=15.9510(15)Å b=5.9914(6)Å c=23.071(2)Å
α=90.00° β=103.494(4)° γ=90.00°
(4-bromo-PhC(CN)(=NOH)), 3-bromo-5-methoxypyridine
(C8H5BrN2O)(C6H6BrNO)
CrystEngComm (2009) 11, 3 439-443
a=6.9907(6)Å b=8.0552(7)Å c=15.3027(13)Å
α=79.305(5)° β=89.038(5)° γ=64.660(5)°
(4-bromo-PhC(CN)(=NOH)), 1-(4-bromobenzyl)-2- methylbenzimidazole
(C8H5BrN2O)(C15H13BrN2)
CrystEngComm (2009) 11, 3 439-443
a=4.9374(6)Å b=22.597(3)Å c=19.233(2)Å
α=90.00° β=96.869(2)° γ=90.00°
(4-bromo-PhC(CN)(=NOH)), 1-(4-bromobenzyl)benzimidazole
(C8H5BrN2O)(C14H11BrN2)
CrystEngComm (2009) 11, 3 439-443
a=5.3033(6)Å b=13.2294(15)Å c=15.0601(17)Å
α=102.536(2)° β=99.505(2)° γ=94.752(2)°
(2-fluoro-PhC(CN)(=NOH))2, 1,2-di(4-pyridyl)ethene
(C8H5N2OF)2(C12H10N2)
CrystEngComm (2009) 11, 3 439-443
a=3.8189(6)Å b=11.2941(18)Å c=14.107(2)Å
α=98.884(10)° β=93.147(11)° γ=94.624(10)°
4-bromo-PhC(CN)(N=OH), (3-((5,6-dimethylbenzimidazol-1- yl)methyl)PhCN
(C8H5N2OBr)(C17H15N3)
CrystEngComm (2009) 11, 3 439-443
a=6.039(3)Å b=13.982(6)Å c=14.166(6)Å
α=70.067(19)° β=83.78(3)° γ=82.22(3)°
481 1,4-di((1-benzimidazolyl)methyl)benzene, (3-chloro- PhC(CN)(=NOH))2
(C22H18N4)(C8H5N2OCl)2
CrystEngComm (2009) 11, 3 439-443
a=13.6335(10)Å b=4.4402(3)Å c=27.297(2)Å
α=90.00° β=94.084(3)° γ=90.00°
MS 512 1-(4-pyridylmethyl)-5,6-Me2benzimidazole, 4-F- PhC(CN)(NOH)
(C15H15N3)(C8H5N2OF)
CrystEngComm (2009) 11, 3 439-443
a=16.1659(12)Å b=6.4146(5)Å c=21.0074(16)Å
α=90.00° β=105.945(5)° γ=90.00°
(1,3-Ph2acac)Co(II), 4-[(2-MeBenzIm)methyl]PhCONH2 (THF)
Co(C15H11O2)2(C16H15N3O)2(C4H8O)2
Inorganic Chemistry (2009) 48, 4052-4061
a=8.9670(6)Å b=11.2006(7)Å c=15.3238(9)Å
α=75.533(3)° β=80.377(4)° γ=79.221(4)°
(1,3-Ph2acac)Ni(II), 4-[(2-MeBenzIm)methyl]PhCONH2 (THF)2
Ni(C15H11O2)2(C16H15N3O)2(C4H8O)2
Inorganic Chemistry (2009) 48, 4052-4061
a=8.9948(19)Å b=11.185(2)Å c=15.409(3)Å
α=75.737(9)° β=79.844(13)° γ=78.971(16)°
Cu{[4-(5,6-dimethylbenzimidazol-1-yl)methyl]benzamide}2(F6-acac)2 (CH3CN)2
Cu(C17H17N3O)2(C5HO2F6)2(C2H3N)2
Inorganic Chemistry (2009) 48, 4052-4061
a=10.349(3)Å b=10.688(3)Å c=12.680(3)Å
α=98.217(6)° β=110.457(5)° γ=104.465(5)°
{3-[(pyrazol-1-yl)methyl]benzamide}2 (F6-acac)4 Cu(II)2
(C11H11N3O)2(C5H1F6O2)4Cu2
Inorganic Chemistry (2009) 48, 4052-4061
a=9.7354(11)Å b=11.1497(12)Å c=23.870(3)Å
α=90.00° β=96.985(2)° γ=90.00°
Bis{4-[(pyrazol-1-yl)methyl]benzamide} (Ph2-acac)2 Ni(II) bis{ethanol} (Ph2-acac)2 Ni(II)
(C11H11N3O)2(C15H11O2)2Ni(C2H6O)2(C15H11O2)2Ni
Inorganic Chemistry (2009) 48, 4052-4061
a=9.0170(6)Å b=12.3493(8)Å c=17.6357(12)Å
α=86.3190(10)° β=78.0890(10)° γ=72.2410(10)°
{3-[(pyrazol-1-yl)methyl]benzamide}2 (F6-acac)4 Cu(II)2
(C11H11N3O)2(C5H1F6O2)4Cu2
Inorganic Chemistry (2009) 48, 4052-4061
a=10.0325(10)Å b=15.1765(15)Å c=16.6440(16)Å
α=90.00° β=99.957(2)° γ=90.00°
527 4-[(2-phenylimidazol-1-yl)methyl]benzamide, mu-Cu2(F-PhCOO)4
(C17H15N3O)2(C7H4O2F)4Cu2(C2H3N)5
Inorganic Chemistry (2009) 48, 4052-4061
a=10.9536(9)Å b=11.2155(8)Å c=14.9765(12)Å
α=77.570(6)° β=78.159(4)° γ=74.526(5)°
BS-2-11e mu(o-FPhCOO)4 Cu2[4-imidazolylmethylbenzamide]2
(C11H11N3O)2Cu2(C7H4O2F)4
Inorganic Chemistry (2009) 48, 4052-4061
a=10.8218(9)Å b=19.4000(14)Å c=12.0541(8)Å
α=90.00° β=108.346(4)° γ=90.00°
BS-3-44-2A 4-[(pyrazol-1-yl)methyl]PhCONH2, mu4-(AcO)Cu CH3CN
(C11H11N3O)2Cu2(C2H3O2)4(C2H3N)2
Inorganic Chemistry (2009) 48, 4052-4061
a=7.5896(5)Å b=10.0990(7)Å c=13.3959(8)Å
α=68.531(4)° β=82.310(3)° γ=72.114(3)°
Mu(OAc)4 Cu2 {3-[(pyrazol-1-yl)methyl]benzamide}2
(C2H3O2)4Cu2(C11H11N3O1)2
Inorganic Chemistry (2009) 48, 4052-4061
a=8.0173(4)Å b=10.1615(5)Å c=11.4846(6)Å
α=110.1640(10)° β=109.1250(10)° γ=90.5040(10)°
(4-bromo-phenylacetonitrile oxime)2, 1,4-di[(1-benzimidazolyl)methyl]benzene
(C8H5BrN2O)2(C22H18N4)
Crystal Growth & Design (2006) 6, 4 1033
a=11.436(4)Å b=5.640(2)Å c=26.449(9)Å
α=90.00° β=99.252(5)° γ=90.00°
(4-bromo-PhC(CN)(=NOH))2, 1,4-di[(2-methyl-1-benzimidazolyl)methyl]benzene
(C8H5BrN2O)2(C24H22N4)
Crystal Growth & Design (2006) 6, 4 1033
a=7.4360(9)Å b=19.613(2)Å c=12.5107(15)Å
α=90.00° β=107.063(2)° γ=90.00°
(4-bromo-PhC(CN)(=NOH))2, 1,4-di[(2-methyl-1-imidazolyl)methyl]benzene
(C8H5BrN2O)2(C16H18N4)
Crystal Growth & Design (2006) 6, 4 1033
a=7.0034(8)Å b=10.6013(12)Å c=11.1605(12)Å
α=77.000(2)° β=75.995(2)° γ=84.920(2)°
(3-chloro-phenylacetonitrile oxime)2, 1,4-di[(1-imidazolyl)methyl]benzene
(C8H5ClN2O)2(C14H14N4)
Crystal Growth & Design (2006) 6, 4 1033
a=5.9000(10)Å b=7.2231(12)Å c=17.088(3)Å
α=86.114(3)° β=89.633(4)° γ=73.472(3)°
1,4-[bis(2-methylbenzimidazol-1-yl)methyl]benzene, (4-bromobenzacetoxime)2
(C24H22N4)(C8H8NOBr)2
Crystal Growth & Design (2006) 6, 4 1033
a=10.9286(11)Å b=14.1612(15)Å c=11.3704(12)Å
α=90.00° β=92.619(2)° γ=90.00°
528 3-[(2-phenylimidazol-1-yl)methyl]benzamide, Cu2(2-FC6H4COO)4 (CH3CN)2
(C17H15N3O)2Cu2(C7H4O2F)4(C2H3N)4
Inorganic Chemistry (2009) 48, 4052-4061
a=10.9819(16)Å b=11.2072(15)Å c=14.926(2)Å
α=99.042(8)° β=91.419(6)° γ=116.183(7)°
(4-bromo-phenylacetonitrile oxime)2, 1,4-di[(1-imidazolyl)methyl]benzene
(C8H5BrN2O)2(C14H14N4)
Crystal Growth & Design (2006) 6, 4 1033
a=12.9436(5)Å b=5.1863(2)Å c=21.6419(9)Å
α=90.00° β=93.4500(10)° γ=90.00°